ARPA-H, diversity in clinical trials bills advance through committee

ACA Marketplace enrollees are pinched by steeper healthcare costs, KFF follow-up survey finds

Four out of five people returning to the ACA Marketplace say their healthcare costs are “higher,” compared to last year, according to a survey conducted by Kaiser Family Foundation in mid-February and early March. More than half of respondents reported these costs (premiums, deductibles, co-pays, or coinsurance) were “a lot higher.”

House bill proposes to exempt health care workers from H-1B visa $100,000 fee

The H–1Bs for Physicians and the Healthcare Workforce Act—introduced by Rep. Sanford D. Bishop, Jr. (D-GA) and Rep. Mike Lawler (R-NY)—would exempt physicians and health care workers from a recently imposed $100,000 fee now required to obtain an H-1B visa, which allows foreign nationals in “specialty occupations” to live and work in the U.S. The fee was previously $5,000 to $10,000.

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Drugs & Targets

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.

March 20, 2026

Vol.52 No.11

In Brief

ARPA-H launches program to supercharge biosensor device development with next-gen platform

The Advanced Research Projects Agency for Health, an agency within HHS, announced the launch of its Delphi program, an initiative to advance low-cost biosensors that can monitor hormones, inflammatory markers, and other important biochemical signals.

March 13, 2026

Vol.52 No.10

ARPA-H, diversity in clinical trials bills advance through committee

YOU MAY BE INTERESTED IN

ACA Marketplace enrollees are pinched by steeper healthcare costs, KFF follow-up survey finds

House bill proposes to exempt health care workers from H-1B visa $100,000 fee

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

START, Trialing collaborate to expand access to oncology clinical trials across Europe

ARPA-H launches program to supercharge biosensor device development with next-gen platform

Renew today!

Subscriber content

Never miss an issue!

Login